Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials

By sjmartinez • November 28, 2024

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4688. Epub ahead of print. PMID: 39602111.

Tags: Dermatology, Olive View DoM, Publications

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients[...]

Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States

Kingston P, Peterson H, Lee K, Huang MY, Yee D, Korouri E, Armstrong AW. Gender differences in pain interference with daily activities and functional impairment[...]

Artificial Intelligence and Dermatology

Wongvibulsin S, Lee I. Artificial Intelligence and Dermatology. JAMA Dermatol. 2025 Jan 8. doi: 10.1001/jamadermatol.2024.4645. Epub ahead of print. PMID: 39774621.